Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — H1 2021 Earnings Presentation
30 slides from Indivior Pharmaceuticals's earnings presentation, Jul 29, 2021
Slide 1: Q2 / H1 2021 Results
Indivior PLC Q2 / H1 2021 Results July 29, 2021
Slide 2: Agenda
AGENDA Overview & Strategic Priorities Mark Crossley Q2 / H1 Performance & FY 2021 Guidance Ryan Preblick R&D Update Christian Heidbreder Conclusion Mark Crossley Q&A
Slide 3: Mark Crossley, Chief Executive Officer
Mark Crossley Chief Executive Officer
Slide 4: Forward-looking statements
Forward-looking statements This announcement contains certain statements that are forward-looking. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from
Slide 5: Q2 2021 key takeaways
Q2 2021 key takeaways Good execution across all Strategic Priorities Organized Health System (OHS) focus for SUBLOCADE® delivering Moving forward with confidence – initiating $100m share repurchase program 5
Slide 6: Strategic Priorities report card: Q2 2021
Strategic Priorities report card: Q2 2021 1 2 3 4 Grow SUBLOCADE® >$1 bil. Diversify Revenue Build Our Pipeline Optimize Operating Model • Q2 21 NR: $61m • SUBUTEX® Prolonged Release • SUBLOCADE® Post Marketing • Cash: $1bn +42% vs. Q1 21; (ROW): Commitments: All approved by FDA +$142m vs. FYE 2020
Slide 7: Ryan Preblick, Chief Financial Officer
Ryan Preblick Chief Financial Officer
Slide 8: Profit & Loss Account
Profit & Loss Account* Q2 H1 2021 2020 % 2021 2020 % Adjusted Adjusted change Adjusted Adjusted change ($ in mil. at actual FX) Net Revenues 201 150 34% 381 303 26% Cost of Sales (30) (19) (62) (35) Gross Profit 171 131 31% 319 268 19% Gross Margin (%) 85% 87% -200bps 84% 88% -400bps Selling, Genera
Slide 9: Cash & borrowing position
Cash & borrowing position H1 FY • Net cash growth to $750m (vs. $623m at FY 2020): ($ in mil.) 2021 2020 ✓ Better H1 2021 operating performance Cash & Cash Equivalents $1,000 $858 ✓ Stable government payables • Maintaining disciplined & balanced cash stance: ✓ Deliver against SUBLOCADE® net rev. goa
Slide 10: Term Loan Replacement
Term Loan Replacement Debt maturity extension to June 2026 Balloon payment deferred from December 2022 Greater flexibility to utilize the Leverage covenant threshold removed Company’s cash enabled by extending maturity and Lower annual mandatory principal prepayments removing leverage covenant Liqui
Slide 11: Upgraded FY 2021 guidance reiterated
Upgraded FY 2021 guidance reiterated FY 21 Guidance ($ in mil.) Total NR $705m to $740m • SUBLOCADE NR • $210m to $230m • PERSERIS NR • $17m to $20m Adj. gross margin Low 80% range Adj. OPEX (SG&A + R&D) $470m to $480m Adj. pre-tax income Positive Additional top-line items: Margin & Expense detail:
Slide 12: Christian Heidbreder, Chief Scientific Officer
Christian Heidbreder Chief Scientific Officer
Slide 13: Today's Update
TODAY’S UPDATE → Disease State → Pipeline Update → Peer-Reviewed Publications & Conferences Q2-2021 Results R&D Update - July 29th, 2021 - Strictly Confidential - For Discussion Purpose Only
Slide 14: Disease State
Disease State “2 INDIVIOR AS
Slide 15: Unprecedented number of reported drug overdose deaths in the US
UNPRECEDENTED NUMBER OF REPORTED DRUG OVERDOSE DEATHS IN THE US → GROWING IMPACT OF SYNTHETIC OPIOIDS 100000 90722 92,183 90000 80000 72106 70122 68,821 67697 67574 70000 65571 60000 55363 56,688 52902 51003 47523 47549 46996 50000 43691 37563 40000 33203 31585 28986 28731 30000 20932 20000 9946 100
Slide 16: Alcohol Use Disorder: 14.5M people aged 12+ in the US
ALCOHOL USE DISORDER (AUD): IN THE US, 14.5M PEOPLE AGED 12> HAD AUD IN THE PAST YEAR Source: Substance Abuse and Mental Health Services Administration. (2020). Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publ
Slide 17: Cannabis-related disorders are on the rise
CANNABIS-RELATED DISORDERS ARE ON THE RISE: 4.8 MIL. PEOPLE HAD A PAST-YEAR CANNABIS USE DISORDER (CUD) IN THE US* Cannabis potency (% Δ-9 THC) quadrupled in Adjusted odds ratio of psychotic disorders for combined Rates of hospitalizations (HD) and emergency past 20 years frequency & type of cannabi
Slide 18: Pipeline Update
Pipeline Update “2 INDIVIOR AS
Slide 19: SUBLOCADE, SUBOXONE Film & PERSERIS
SUBLOCADE®, SUBOXONE® FILM & PERSERIS® SUBLOCADE® in the US → US Label updates: FDA approvals Region SUBLOCADE® Approvals SUBOXONE® Film Region – Transition to SUBLOCADE from SL Approvals Canada ✓ November 21, 2018 buprenorphine: May 11, 2021 Israel ✓ April 07, 2020 – Buprenorphine-Fentanyl interact
Slide 20: Indivior current pipeline
INDIVIOR CURRENT PIPELINE →Phase 1 Single Ascending Dose (SAD) study has completed and shows Opioid Use Disorder (OUD) encouraging safety and pharmacokinetics in healthy volunteers. The final Clinical Study Report is expected by the end of Q4-2021. INDV-2000 (Selective Orexin-1 →Phase 1 Multiple Asc
Slide 21: Conclusion
Conclusion SZ INDIVIOR AS
Slide 22: SUBOXONE Film indication and safety information
SUBOXONE® (BUPRENORPHINE AND NALOXONE) SUBLINGUAL FILM (CIII) INDICATION AND USAGE SUBOXONE® Film is indicated for treatment of opioid dependence. SUBOXONE Film should be used as part of a complete treatment plan that includes counseling and psychosocial support HIGHLIGHTED SAFETY INFORMATION Prescr
Slide 23: SUBLOCADE indication and safety information
SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use (CIII) INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment f
Slide 24: About PERSERIS indication and safety information
ABOUT PERSERIS® (risperidone) for extended-release injectable suspension INDICATION PERSERIS® (risperidone) is indicated for the treatment of schizophrenia in adults. WARNING: INCREASED MORTALITY IN ELDERY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed w
Slide 25: Appendix
Appendix So INDIVIOR
Slide 26: Q2 Profit & Loss Account Reconciliation
Q2 Profit & Loss Account Reconciliation Q2 2021 Q2 2020 Q2 2021 Q2 2021 Q2 2020 Q2 2020 Adjustments Adjustments Actual Adjusted Actual Adjusted ($ in mil.) Net Revenues 201 201 150 150 Cost of Sales (30) (30) (18) (1) (1) (19) Gross Profit 171 171 132 131 Selling, General and Administration Expenses
Slide 27: H1 Profit & Loss Account Reconciliation
H1 Profit & Loss Account Reconciliation H1 2021 H1 2020 H1 2021 H1 2021 H1 2020 H1 2020 Adjustments Adjustments Actual Adjusted Actual Adjusted ($ in mil.) Net Revenues 381 381 303 303 Cost of Sales (62) (62) (41) 6 (1) (35) Gross Profit 319 319 262 268 Selling, General and Administration Expenses (
Slide 28: H2 Capital Markets Calendar
H2 21 Capital Markets Calendar September 2021 October 2021 November 2021 S M T W T F S S M T W T F S S M T W T F S 1 2 1 2 3 4 5 6 1 2 3 4 3 4 5 6 7 8 9 Market Holiday 5 6 7 8 9 10 11 7 8 9 10 11 12 13 10 11 12 13 14 15 16 Key IR Date 12 13 14 15 16 17 18 14 15 16 17 18 19 20 17 18 19 20 21 22 23 19
Slide 29: Peer-Reviewed Publications 2021
PEER-REVIEWED PUBLICATIONS 2021 Le Moigne A et al. (2021) Reanalysis of a phase 3 trial of a monthly extended- Algera MH et al. (2021) Tolerance to opioid-induced respiratory depression in release risperidone injection for the treatment of acute schizophrenia. J Clin chronic high-dose opioid users:
Slide 30: Conferences 2021
Joint Federal Pharmacy CONFERENCES 2021 Nov 14-17 Seattle ISAM 19 – 21 Nov Poster/ Podium presentation Malta Booth/Table EUROPAD 19-21 Nov Symposium Grenoble SiPaD NCCHC 10-12 Nov Oct 31-Nov 4 Rome Las Vegas DGS ASAM APNA 5-7 Nov April 22-25 Oct 13-16 Berlin Virtual Louisville FederserD CPNP APNA AM